

In addition to the established SupraVail® family of formulation strategies, Phares offers a range of conventional compounding technologies for poorly soluble actives.
Phares works together with its clients to choose the right formulation for the right phase of development. Sometimes one certain formulation strategy is more advantageous to obtain initial preclinical results, while another formulation may be recommendable for clinical development.
For more information, click here to download the Conventional Formulation Technologies Brochure.
BioPharm America
Atlanta, Georgia
September 9-10, 2008
AAPS
Atlanta, Georgia
November 16-20, 2008
BIO-Europe
Mannheim/Heidelberg, Germany
November 17-19, 2008